现代多发性骨髓瘤治疗的心血管并发症:一项药物警戒研究
本研究基于美国FDA不良事件报告系统(FAERS)数据库,分析2015年后获批的4种新型多发性骨髓瘤药物的心血管不良事件。通过计算报告比值比(ROR)及95%置信区间(CI),发现埃罗妥珠单抗、伊沙佐米、达雷妥尤单抗和帕比司他均与心房颤动、心力衰竭和冠状动脉疾病风险显著相关,提示临床使用这些药物时应关注患者心脏病史。
要点
- 埃罗妥珠单抗、达雷妥尤单抗和帕比司他与心房颤动风险显著相关,ROR分别为5.8、4.8和5.7。
- 埃罗妥珠单抗和达雷妥尤单抗与心力衰竭风险显著相关,ROR分别为8.2和5.8。
- 帕比司他与冠状动脉疾病风险显著相关,ROR为4.6。
核心结论
- 部分新型抗骨髓瘤药物与既往未明确的心血管毒性显著相关。
- 使用这些新型药物时应考虑患者的心脏病史。
研究设计与样本
- 基于美国FDA不良事件报告系统(FAERS)数据库的药物警戒研究。
- 分析2015年至2020年获批的4种新型多发性骨髓瘤药物。
- 计算报告比值比(ROR)及95%置信区间(CI)。
主要发现
- 埃罗妥珠单抗、伊沙佐米、达雷妥尤单抗和帕比司他心房颤动的ROR(95%CI)分别为5.8(4.4-7.7)、1.9(1.5-2.3)、4.8(4.2-5.6)和5.7(4.1-8.1)。
- 上述四种药物心力衰竭的ROR(95%CI)分别为8.2(6.4-10.5)、4.7(4.1-5.4)、5.8(4.9-6.7)和5.6(3.8-8.1)。
- 上述四种药物冠状动脉疾病的ROR(95%CI)分别为2.7(1.9-3.9)、2.7(2.3-3.2)、2.3(1.9-2.8)和4.6(3.2-6.6)。
临床怎么用
- 使用埃罗妥珠单抗、伊沙佐米、达雷妥尤单抗或帕比司他前应评估患者心脏病史。
- 治疗期间应监测心房颤动、心力衰竭和冠状动脉疾病相关症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Multiple myeloma accounts for over 10-15% of haematological malignancies. Continued molecular advances have resulted in the development of new drugs for treatment of multiple myeloma. Four drugs were approved by the Food and Drug Administration (FDA) in 2015, but their safety is not well defined. The aim of this study is to delineate the cardiovascular adverse events of these drugs. METHODS: We reviewed the adverse cardiac events of newly approved FDA drugs since 2015 using the US FDA Adverse Events Reporting System (FAERS) database. We calculated the reporting odds ratio (ROR) with 95% confidence interval (CIs) for the drugs that have the highest incidence of cardiovascular adverse events. RESULTS: Among the medications that have approved for multiple myeloma between 2015 and 2020, 4 novel drugs showed the highest incidence of cardiotoxicity. ROR (95% CI) for atrial fibrillation due to elotuzumab, ixazomib, daratumumab and panobinostat compared to other FAERS drugs was 5.8 (4.4-7.7), 1.9 (1.5-2.3), 4.8 (4.2-5.6) and 5.7 (4.1-8.1), respectively. The ROR (95% CI) for cardiac failure was 8.2 (6.4-10.5), 4.7 (4.1-5.4), 5.8 (4.9-6.7) and 5.6 (3.8-8.1) and ROR (95% CI) for coronary disease was 2.7 (1.9-3.9), 2.7 (2.3-3.2), 2.3 (1.9-2.8) and 4.6 (3.2-6.6) due to elotuzumab, ixazomib, daratumumab and panobinostat compared to all other drugs in FAERS. CONCLUSION: Our results demonstrated that certain newly approved antimyeloma therapies are significantly associated with previously unknown cardiotoxicity. These results warrant further studies and highlight the importance of considering the cardiac history of patients with multiple myeloma when utilizing these novel agents.
引用
- Al-Yafeai Z, Ghoweba M, Ananthaneni A, et al. Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study. Br J Clin Pharmacol. 2022. PMID: 35996166. doi:10.1111/bcp.15499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。